Spasticity is a common consequence of neurological disorders, such as stroke,5 and presents as intermittent or sustained involuntary activation of muscles6
Spasticity primarily affects the elbow, wrist and ankle7
If left untreated, spasticity can cause shortening of muscles and tendons, and a vicious cycle can develop8
Adapted from Royal College of Physicians. Spasticity in adults: management using botulinum toxin, 20188
Features of spasticity8
Prevalence of PSS increases with post-stroke survival time9
Adapted from Wissel J et al, 20139
Data on the time course of post-stroke spasticity was compiled, via a literature search, from nine studies using the Modified Ashworth Scale and the Tone Assessment Scale for monitoring increased muscle tone.9
A timely diagnosis may avoid worsening of untreated spasticity10
Neural changes may drive the onset of post-stroke spasticity11,12
If patients are not treated in a timely manner, their spasticity is likely to become more disabling over time, causing pain, deformity and contracture10
Intrinsic muscle changes between 3 and 18 months may lead to chronic severe spasticity, preventing a full recovery9,11,12
Rehabilitation therapies applied within the first 3 months after stroke are likely to deliver benefit16
PSS: post-stroke spasticity.
BOTOX® (botulinum toxin type A) is indicated for the treatment of focal spasticity including:17
wrist and hand disability due to upper limb spasticity associated with stroke in adults
ankle and foot disability due to lower limb spasticity associated with stroke in adults
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at [email protected]
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle:
▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at [email protected]